RxDoctor Payments Data

Ashlee Waugh, MD

Internal Medicine · Edmond, OKNPI 1831308899

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,581 of the $14,631 with a category attached, or 65.5%. 60 manufacturers reported payments, led by Merz North America, Inc. at 34.2% of the total. Reporting peaked in 2023 at $6,665 and has fallen 76.4% since, to $1,574 in 2025. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,631in general payments, 2019–2025

Across 576 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$5K
  • AbbVie$2K
  • Novo Nordisk$767
  • Lilly USA, LLC$630
  • Otsuka America Pharmaceutical, Inc.$592
  • IBSA Pharma Inc.$422
  • plus $5K from 54 others

What the payments were for

  • Consulting fees$5,00034%
  • Food & beverage$9,58165%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merz North America, Inc.1$5,000
AbbVie(2 entities)146$2,243
Novo Nordisk54$767
Lilly USA, LLC41$630
Otsuka America Pharmaceutical, Inc.36$592
IBSA Pharma Inc.24$422
Axsome Therapeutics, Inc.18$393
Pfizer16$278
Takeda Pharmaceuticals U.S.A., Inc.13$270
Lundbeck LLC12$245
Amneal Pharmaceuticals LLC13$235
GSK12$206
Radius Health, Inc.8$179
Amgen(2 entities)11$179
Corcept Therapeutics7$151
Astellas Pharma US Inc8$151
Azurity Pharmaceuticals, Inc.8$149
Arbor Pharmaceuticals, Inc.10$140
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$129
Currax Pharmaceuticals LLC8$128
Therapeuticsmd, Inc.8$119
Teva Pharmaceuticals USA, Inc.8$118
Antares Pharma, Inc.6$114
Exact Sciences5$88
Corium, LLC5$82
Ironwood Pharmaceuticals, Inc4$73
Alfasigma USA, Inc.1$72
Supernus Pharmaceuticals, Inc.4$71
Idorsia Pharmaceuticals US Inc4$69
Noven Therapeutics, LLC4$67
Upsher-smith Laboratories LLC3$66
Sumitomo Pharma America, Inc.3$64
Abbott3$61
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$60
Bayer3$53
Kowa Pharmaceuticals America, Inc.3$50
Acella Pharmaceuticals, LLC3$50
Vertical Pharmaceuticals, LLC2$43
Biohaven Pharmaceutical Holding Company Ltd.2$42
Johnson & Johnson(2 entities)3$40
Ardelyx, Inc.2$38
Tris Pharma Inc2$35
Nestle Healthcare Nutrition Inc.2$35
Avion Pharmaceuticals2$35
Boehringer Ingelheim2$34
Neos Therapeutics, LP2$34
Jazz Pharmaceuticals Inc.2$34
Intra-sana Laboratories2$32
Adlon Therapeutics L.p.2$31
ANI Pharmaceuticals, Inc.1$31
Impel Pharmaceuticals Inc.2$30
Dexcom, Inc.1$29
Millicent US Inc2$29
Merck2$28
Eisai Inc.2$25
Shire North American Group Inc1$22
Mayne Pharma Commercial LLC2$21
Collegium Pharmaceutical, Inc.1$20
Mission Pharmacal Company1$19
Halozyme Inc1$19

How this compares

$14,631 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$16,525
Medicare patients
88
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$67,353
OzempicSemaglutide14$13,021
VyvanseLisdexamfetamine Dimesylate19$7,146
ProgesteroneProgesterone, Micronized138$3,541
SynthroidLevothyroxine Sodium33$2,949
Lisdexamfetamine Dimesylate19$2,714
Estradiol (Once Weekly)Estradiol45$2,452
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$2,241
Testosterone Cypionate63$2,239
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,069
Levothyroxine Sodium110$1,001
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$968
Np ThyroidThyroid,pork18$937
Estradiol27$765
Bupropion XlBupropion Hcl16$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$630$67,35349 claims
Novo NordiskOzempic$767$13,02114 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$270$7,14619 claims
AbbVieSynthroid$2,243$2,94933 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$235$1,001110 claims
Acella Pharmaceuticals, LLCNp Thyroid$50$93718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →